Meibomian Gland Dysfunction (MGD) is the most common cause of chronic dry eye — and the most underdiagnosed. If your eyes burn, water uncontrollably, or blur up after a few hours of screen time, MGD is the most likely culprit. Dr. Y. Shira Kresch, OD MS evaluates and treats MGD as a primary clinical focus at our Southfield, MI clinic, using advanced diagnostic imaging and FDA-cleared in-office treatments that address the root cause of the disease.
Meibomian Gland Dysfunction (MGD) is the leading cause of evaporative dry eye disease — responsible for roughly 80% of chronic dry eye cases. It’s also one of the most underdiagnosed eye conditions in adults, because the early signs are easy to dismiss and proper diagnosis requires imaging equipment most routine practices don’t have on site.
At 1-800-Dry-Eyes Specialty Vision Institute in Southfield, MI, Dr. Y. Shira Kresch, OD MS evaluates and treats MGD as a primary clinical focus. This page walks through what MGD is, how it develops, how we diagnose it, and what your treatment options look like once we know exactly what’s going on.
Your upper and lower eyelids contain rows of tiny oil-producing glands called Meibomian glands — about 25 to 40 of them per lid. With every blink, these glands release a thin layer of clear oil (called meibum) onto the surface of your tear film.
That oil layer is critical. It’s what keeps your tears from evaporating between blinks. Without a healthy oil layer, even normally produced tears dry off the surface of the eye in seconds, leaving the cornea exposed and inflamed.
In Meibomian Gland Dysfunction, the glands become blocked, inflamed, or structurally damaged. The oil they produce becomes thicker and waxy — or stops flowing entirely. Over months and years, glands that don’t drain regularly begin to atrophy. Severe, long-standing MGD can permanently shorten or destroy the glands, which is why early intervention matters so much.
MGD progresses gradually, and the symptoms vary from patient to patient. The most common signs include:
If you’ve been told you “just have dry eye” and handed a sample of artificial tears, you haven’t been evaluated for MGD specifically. The two conditions overlap heavily but require different treatment.
MGD develops from a combination of internal and external factors. The most common contributors we see in our Southfield clinic include:
In most patients, MGD develops from a combination of these factors rather than a single cause. Identifying which ones apply to you shapes the treatment plan.
A proper MGD evaluation isn’t a quick look with a slit lamp. At your comprehensive dry eye evaluation, Dr. Kresch uses advanced diagnostic imaging and structured testing to map the condition of your glands in detail. This may include:
The goal of the evaluation isn’t to confirm a label — it’s to understand the specific mechanism driving your symptoms so the treatment plan addresses the cause, not just the surface complaint.
Treating MGD effectively requires a multi-modal approach. Eye drops on their own — even prescription ones like Restasis or Xiidra — typically aren’t enough to restore gland function, because they don’t physically reopen blocked glands or address the inflammation in the surrounding tissue. If you’ve been on prescription drops for months without meaningful improvement, you may find our discussion helpful: Restasis Isn’t Working: When to Try Something Else.
Depending on the severity and root cause of your MGD, Dr. Kresch may recommend one or more of the following:
IPL delivers calibrated pulses of broad-spectrum light to the skin around the eyes. It targets the inflammatory blood vessels driving MGD, eliminates Demodex mites at the lash base, and stimulates the Meibomian glands to resume normal oil flow. IPL is typically performed as a series of 3–4 sessions spaced several weeks apart.
RF therapy uses gentle, temperature-controlled heat to liquefy the hardened, waxy oils trapped inside blocked Meibomian glands. Unlike warm compresses applied at home, RF reaches the therapeutic temperatures necessary to actually melt the obstruction — and it does it consistently across the entire eyelid.
LLLT (also called photobiomodulation) uses specific wavelengths of light to stimulate cellular energy production within the Meibomian glands, increase blood flow, and reduce inflammation at the cellular level. LLLT is often combined with IPL and RF as part of a multi-modal protocol.
In-office expression of the Meibomian glands — performed by Dr. Kresch under controlled pressure after the glands have been warmed — physically clears blockages and restores oil flow. This is typically combined with one of the energy-based therapies above for lasting effect.
Daily warm compresses, lid hygiene, and (in some cases) prescription eye drops or omega-3 supplementation are part of nearly every MGD treatment plan. These don’t replace in-office treatment, but they extend and maintain results between sessions.
Meibomian glands that have already atrophied cannot be regrown. Once the structure of the gland is lost, no therapy currently available will rebuild it. This is the single most important reason to evaluate and treat MGD early — before gland dropout becomes permanent.
Patients who come in with mild-to-moderate MGD almost always respond well to treatment, and we can often stabilize their gland function for decades. Patients who come in with severe, long-standing MGD can still get significant symptom relief, but we may be working with fewer functional glands than we’d like. Earlier is always better.
MGD is the leading cause of Evaporative Dry Eye — see that page for the broader context of evaporative tear film disease. For an overview of how IPL, RF, LLLT, and other modalities work together to treat MGD, see our Combined Dry Eye Treatment Protocol page.
Meibomian gland expression is one of the most important steps in both diagnosing and treating Meibomian Gland Dysfunction. It means applying gentle, controlled pressure to the eyelid to see how readily the glands release their oil (meibum) — and, when the glands are blocked, to physically clear them.
Expression of the Meibomian glands serves two distinct purposes:
The results of gland expression are scored on a standardized scale (see grading below), which lets us track your progress objectively from visit to visit rather than relying on symptoms alone. This is why in-office diagnostic expression is a core part of every MGD evaluation — and why at-home warm compresses, which rarely reach the temperature needed to soften hardened meibum, usually can’t reproduce the effect of professional expression.
MGD grading gives your dry eye specialist an objective, repeatable measure of how advanced your Meibomian Gland Dysfunction is — which directly shapes your treatment plan and lets us measure improvement over time. At our Southfield clinic we grade MGD across several dimensions, following the framework established by the International Workshop on Meibomian Gland Dysfunction.
These scores combine into an overall MGD stage — from mild (Stage 1) through severe (Stage 4) — that guides how aggressive treatment needs to be. Milder stages often respond to a short course of IPL and lid therapy, while advanced stages with significant gland dropout call for a combined IPL + RF + LLLT protocol and closer long-term monitoring. Because grading is objective, it is also the clearest way to show that treatment is working: rising expressibility and improving meibum quality confirm your glands are recovering.
Q: How do I know if I have MGD rather than regular dry eye? You can’t reliably tell the difference based on symptoms alone — they overlap almost completely. The only way to confirm MGD is through meibography and gland expression testing during a comprehensive dry eye evaluation. If your eye doctor has never imaged your Meibomian glands, you haven’t been evaluated for MGD specifically.
Q: Will eye drops cure my MGD? No. Eye drops can temporarily relieve symptoms, but they don’t address the underlying gland blockage or inflammation. Restasis and Xiidra reduce inflammation but don’t unclog glands. Effective treatment requires physically opening the blocked glands and addressing the inflammation in the surrounding tissue — which is what in-office treatments like IPL, RF, and LLLT are designed to do.
Q: Are warm compresses enough to treat MGD? Warm compresses at home can help with very mild MGD, but most home compresses don’t reach therapeutic temperatures (over 108°F) or maintain that heat long enough to actually melt hardened meibum. They’re useful as maintenance between in-office treatments, but rarely sufficient on their own for moderate or severe MGD.
Q: Is MGD reversible? Gland function can be substantially restored if you intervene before the glands atrophy. Once glands have shortened or disappeared from meibography imaging, that loss is permanent. The earlier you treat MGD, the better your long-term outcome.
Q: How long does treatment take? Most patients undergo an initial series of 3–4 in-office treatments (IPL, RF, LLLT, or a combination) spaced 2–4 weeks apart. Many patients notice symptom improvement after the first or second session, with cumulative results building through the series. Maintenance treatments every 6–12 months help preserve long-term results.
Q: Does insurance cover MGD treatment? The diagnostic portion of your evaluation is typically billed as a medical exam and may be covered by your medical insurance. In-office treatments like IPL, RF, and LLLT are usually considered elective and are not covered. We discuss cost transparently before treatment begins.
Q: I have rosacea on my face. Could that be causing my MGD? Yes — ocular rosacea is one of the strongest drivers of severe MGD. If you have facial rosacea, you should be evaluated for ocular involvement even if your eye symptoms are mild. IPL is particularly effective for rosacea-driven MGD because it treats both the skin and the gland dysfunction simultaneously.
This page reflects current evidence-based practice as of May 2026. Treatment recommendations are individualized — please consult Dr. Y. Shira Kresch for a comprehensive evaluation before pursuing any specific therapy.
